Latest 5-HT3 antagonist Stories
LUGANO, Switzerland, June 2, 2015 /PRNewswire/ -- - First Fixed Dose Combination Targeting Two Key Pathways Involved in CINV Helsinn,
EAST SETAUKET, N.Y., June 1, 2015 /PRNewswire/ -- NSHOA Cancer Center and Heron Therapeutics, Inc.
LUGANO, Switzerland, May 27, 2015 /PRNewswire/ -- The European approval of ALOXI(R) for paediatric use follows the FDA approval in May 2014 of ALOXI(R) for paediatric use
LUGANO, Switzerland, May 19, 2015 /PRNewswire/ -- Helsinn, a Swiss Group focused on building quality cancer care, announced today that three abstracts highlighting new
Company demonstrates dedication to rare cancers WOODCLIFF LAKE, N.J., May 14, 2015 /PRNewswire/ -- Eisai Inc.
-- First New Fixed Combination Targeting Two Critical Pathways Involved in CINV MELBOURNE, Australia and LUGANO, Switzerland, May 8, 2015 /PRNewswire/ -- Australian biopharmaceutical company
CAMBRIDGE, England, May 6, 2015 /PRNewswire/ -- - Primary Endpoint of Preventing Delayed CINV Met With High Significance Acacia Pharma Ltd ("Acacia Pharma"
CAMBRIDGE, England, April 21, 2015 /PRNewswire/ -- Acacia Pharma Ltd ("Acacia Pharma" or "the Company"), the supportive care company developing products for US and international
LUGANO, Switzerland and WOODCLIFF LAKE, N.J., April 15, 2015 /PRNewswire/ -- Helsinn Group and Eisai Inc.
Robert Gardner Law has created a new resource site to investigate claims following a U.S. Justice department criminal plea agreement with GlaxoSmithKline.
- The horn of a unicorn considered as a medical or pharmacological ingredient.
- A winged horse with a single horn on its head; a winged unicorn.